ANOTHER DAY PHARMA LTD

What ANOTHER DAY PHARMA LTD does

Another Day Pharma Ltd is a privately held, clinical-stage pharmaceutical company headquartered in Sevenoaks, United Kingdom, founded in 2024. The company develops BZ371A, a synthetic, non-hormonal peptide derived from the venom of the Brazilian wandering spider (Phoneutria nigriventer), formulated as a topical gel for sexual dysfunction in men and women. BZ371A operates via a novel mechanism — stimulating nitric oxide production and cGMP-mediated endothelial muscle relaxation — that induces erection independently of neural pathways and is complementary to PDE5 inhibitors such as tadalafil.

The company is running two parallel clinical development tracks. The men's track targets post-prostatectomy erectile dysfunction (Phase II completed April 2025 in 74 men, showing 38% success with combination therapy vs 4% with tadalafil alone). The women's track targets Female Sexual Interest/Arousal Disorder (Phase II completed May 2025 in 30 women, showing 86% arousal satisfaction vs 56% placebo), positioning BZ371A as the first therapy to demonstrate significant benefit in premenopausal women with FSIAD. No serious adverse events have been reported across Phase I or Phase II trials. The company is advancing to Phase III and is actively seeking strategic pharmaceutical partners for licensing or co-development.

Another Day Pharma operates with a lean 1–10 employee structure and has not disclosed funding rounds, ownership, or revenue. The revenue model is explicitly oriented toward licensing royalties and strategic partnerships upon regulatory approval, with the company building on foundational R&D originated by Biozeus Biopharmaceuticals. The product is currently pre-revenue, and pricing has not been established.

Name

ANOTHER DAY PHARMA LTD

Legal name

Another Day Pharma Ltd

Website

https://www.anotherdaypharma.com/

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

Another Day Pharma Ltd is a UK-based, pre-revenue clinical-stage pharmaceutical company developing BZ371A, a synthetic non-hormonal peptide topical gel for sexual dysfunction in men and women, currently advancing through Phase III for post-prostatectomy ED and FSIAD.

Ownership category

akta.pro rank

Product category

Sexual Dysfunction Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Peptide therapeutics
• Sexual dysfunction treatment
• Clinical-stage pharmaceutical
• Topical drug delivery
• Erectile dysfunction therapy

Headquarters

HQ city

Sevenoaks

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical stage company developing BZ371A for treatment of sexual dysfunction. The company is seeking strategic partnerships for licensing or co-development of the product. Revenue will be generated through pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Another Day Pharma develops BZ371A, a synthetic, non-hormonal peptide-based topical gel derived from the venom of the Brazilian wandering spider (Phoneutria nigriventer). The product is being advanced through parallel Phase II clinical trials for male post-prostatectomy erectile dysfunction and Female Sexual Interest/Arousal Disorder (FSIAD). The company is pre-revenue and is actively seeking strategic pharmaceutical partners for licensing or co-development of BZ371A.

Product overview

Another Day Pharma Ltd is developing BZ371A, a single core product - a synthetic non-hormonal peptide-based topical gel for sexual dysfunction. The company operates parallel clinical development tracks for men (post-prostatectomy erectile dysfunction) and women (Female Sexual Interest/Arousal Disorder), with both tracks targeting the same drug product (BZ371A) applied via topical gel formulation. The therapy represents a first-in-class treatment with a novel mechanism of action that works independently of neural pathways, offering potential for patients who do not respond to PDE5 inhibitors.

Differentiator

Problem solved

Functional benefit

Products and services

• BZ371A BZ371A is a synthetic, non-hormonal peptide-based topical gel derived from the venom of the Brazilian wandering spider (Phoneutria nigriventer). It works by stimulating nitric oxide production, triggering cGMP which causes endothelial muscle relaxation and increased blood flow, inducing erection independently of neural pathways. The product is being developed for sexual dysfunction in men (post-prostatectomy ED, PDE5-inhibitor resistant ED) and women (FSIAD, including premenopausal).

Quantifiable outcome

• 86% of sexual encounters reported satisfactory arousal with BZ371A vs 56% with placebo (p=0.002) in women with FSIAD
• +3 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Biozeus BiopharmaceuticalscoreStrategic or Co-development PartnerAnother Day Pharma continues the pioneering work of Biozeus, developing BZ371A from a peptide originally derived from the venom of the Brazilian wandering spider into a safe, synthetic, topical therapy. ADP is building upon Biozeus's foundational research and development work.
• Pharmaceutical Licensing/Co-development PartnerscoreOEM/ Whitelabel/ Licensing PartnerCompany is actively seeking strategic partnerships with pharmaceutical companies interested in licensing or co-developing BZ371A. The company is advancing BZ371A into Phase III trials and is looking for partners to support commercialization.

Scale indicators7 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Sprout Pharmaceuticals: Developer of Addyi (flibanserin), the first FDA-approved treatment for hypoactive sexual desire disorder in premenopausal women — the only commercialized peer in female sexual dysfunction and the most directly comparable commercial benchmark.
• Palatin Technologies: Developer of Vyleesi (bremelanotide), an approved therapy for acquired generalized hypoactive sexual desire disorder in premenopausal women — direct competitor in the female sexual dysfunction space.
• Daré Bioscience: Clinical-stage women's health company focused on sexual and vaginal health therapies; comparable in stage, indication focus, and partnering-driven business model for women's sexual health assets.
• Petros Pharmaceuticals: Commercializes STENDRA (avanafil), a PDE5 inhibitor for erectile dysfunction — directly competes with the same patient population Another Day Pharma targets and represents a comparable go-to-market model.
• Vivus: Specialty pharmaceutical company historically focused on ED (Stendra/avanafil co-promotion) and other sexual health indications; small-cap peer with similar therapeutic category focus.

Emerging players

• Biozeus Biopharmaceuticals: Original discoverer/developer of BZ371A; Another Day Pharma is explicitly built on Biozeus's pioneering work and the relationship is the foundational technology transfer for the asset.
• Marius Pharmaceuticals: Specialty pharma developing and commercializing therapies in men's and women's sexual health, including efforts in testosterone and ED — comparable in therapeutic focus and partnership-driven commercialization.

Broad incumbents

• TherapeuticsMD: Women's health-focused pharma company with a portfolio including hormone and reproductive therapies; broader than Another Day Pharma but operates in overlapping women's health channels and patient populations.
• Eli Lilly: Marketer of Cialis (tadalafil), the PDE5 inhibitor used as the comparator and combination partner in Another Day Pharma's trials; sets the standard of care that BZ371A must outperform or complement.
• Pfizer: Original developer of Viagra (sildenafil), the foundational PDE5 inhibitor for ED; defines the commercial benchmark and competitive context for any new sexual dysfunction therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/another-day-pharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ANOTHER DAY PHARMA LTD